Alectinib Highly Active, Safe in Advanced Crizotinib-refractory ALK+ NSCLC

Share this content:
Alectinib is highly active in patients with crizotinib-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
Alectinib is highly active in patients with crizotinib-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), including those with central nervous system (CNS) metastases, a new study published online ahead of print in the Journal of Clinical Oncology has shown.1

Crizotinib, a tyrosine kinase inhibitor (TKI), improves progression-free survival compared with chemotherapy in ALK-rearranged NSCLC, but disease progression typically occurs. Therefore, researchers sought to evaluate the safety and efficacy of alectinib, a potent and selective ALK TKI that possesses excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC.

For the phase 2 study, researchers enrolled 138 patients, of which 84 had CNS metastases and 96 had received prior chemotherapy. All participants received alectinib 600 mg orally twice daily.

Results showed that among the 122 evaluable patients, the overall response rate was 50% (95% CI, 41 - 59) with a median duration of response of 11.2 months (95% CI, 9.6 - not reached). Of those who had prior chemotherapy, the overall response rate was 45% (95% CI, 35 - 55).

RELATED: Definitive Concurrent Chemoradiotherapy, Surgical Resection Offer Similar Benefits

Researchers found that median progression-free survival for all 138 patients was 8.9 months (95% CI, 5.6 - 11.3), and the CNS disease control rate was 83% (95% CI, 74 - 91) with a median CNS duration of response of 10.3 (95% CI, 7.6 - 11.2).

In regard to safety, the most common adverse events associated with alectinib treatment were constipation, fatigue, and peripheral edema. Adverse events were most grade 1 or 2.

Reference

  1. Ou SI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study [published online ahead of print November 23, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.63.9443.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters